In a newly published report on Polycystic Ovary Syndrome (PCOS) Drugs, Persistence Market Research analyzes the PCOS drugs market over an eight-year period from 2016 to 2024 and studies the key drivers and trends impacting the market. The primary objective of the report is to provide updates and information related to market opportunities and useful insights into factors that are significantly transforming businesses and enterprises in the global PCOS market.
Polycystic ovary syndrome (PCOS) – also known as Stein-Leventhal Syndrome – is a common hormonal endocrine disorder that affects women of child bearing age i.e. 15 to 49 years. This disease is characterized by the formation of cysts on the ovaries leading to an insufficiency of the ovulation initiating hormone in the female body. PCOS mainly occurs due to a combination of environmental and genetic factors, which cause an abnormal function of the hormones present in the pituitary gland that regulate ovulation. Few of the symptoms of PCOS include irregular menstruation, excess facial and body hair, infertility, and acne and other skin problems. PCOS is also associated with diseases such as type 2 diabetes, obesity, heart diseases, acute depression, and obstructive sleep apnea.
Currently, there are no specific diagnostic tests available for the detection of PCOS; however, blood tests, physical examination, vaginal ultrasound, and medical history analysis are widely recommended by general physicians and gynecologists. While there is no cure for PCOS, its symptoms and associated conditions can be managed with the help of lifestyle modification activities, weight loss management, and medications. Currently, no drugs are approved by the FDA and EMA for PCOS. However, oral contraceptives, insulin sensitizing agents, and aromatase inhibitors are used as first line agents for the treatment of irregular menstruation, diabetes, and facial hair growth respectively.
This report covers the global PCOS drugs market performance in terms of revenue contribution from various segments. Included in the report is a detailed impact analysis of key trends, drivers, restraints, and opportunities influencing the growth of the global polycystic ovary syndrome drugs market. The report begins with an overview of the polycystic ovary syndrome drugs process and the main reasons why patients worldwide are adopting this process. This section also underlines factors influencing the growth of the global polycystic ovary syndrome drugs market along with detailing of the key trends, drivers, restraints, opportunities, and regulations. The report also provides strategic recommendations for key players in the market to strengthen their footprint and ensure their business stays sustainably profitable.
The next few sections provide a detailed analysis for every segment and sub-segment of the global PCOS drugs market in terms of market size, Y-o-Y growth rate, absolute $ opportunity, market Attractiveness Index, and BPS analysis. The report further highlights the growth trends of the polycystic ovary syndrome drugs market by region and presents a market outlook for 2016–2024 – showcasing key regional trends contributing to the growth of the polycystic ovary syndrome drugs market worldwide, as well as an analysis into the extent to which drivers are influencing this market in each region.
The final section of the report includes detailed company profiles with company-specific long-term and short-term strategies, key offerings, and recent developments in the polycystic ovary syndrome drugs market. Some of the leading companies profiled in the report are Sanofi, Novartis, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and AstraZeneca Plc.
The report considers 2015 as the base year and provides data for the forecast period 2016–2024. To deduce market size, the report considers various viewpoints based on extensive primary and secondary research. The report begins by sizing the current market – a key indicator of how the market is likely to grow during the forecast period. Given the characteristics of the market, the report presents triangulated data on the basis of supply side and demand side analysis and other dynamics of the global polycystic ovary syndrome market. Key indicators such as number of PCOS patients in each year, adoption of treatment, diagnosis rate, etc., have been considered to arrive at the indicated market numbers.
Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of child bearing age (15 to 49 years). This disease is characterized by the formation of cysts on the ovaries leading to an insufficiency of the ovulation initiating hormone in the female body. The global market for PCOS drugs is on an upward swing given the increasing number of cases of patients inflicted with the disease. The global polycystic ovary syndrome drugs market revenue is estimated to reach US$ 1,154.8 Mn by 2024, expanding at a CAGR of 4.6% during the forecast period (2016–2024).
Key market dynamics
Growth of the global PCOS drugs market is mainly driven by increasing prevalence of the disease and a growing awareness among the patient population. PCOS often leads to hirsutism, obesity, and infertility and hence the need for effective management of associated diseases is likely to boost the demand for PCOS drugs. Also, a growing popularity of combination drugs and their rising adoption among the patient population is expected to boost revenue growth of the PCOS drugs market in the coming years. However, lack of FDA approved drugs and increasing side effects associated with generics might hamper market growth during the forecast period.
Market forecast by segmentation
The global PCOS drugs market is segmented based on Drug Class (Oral Contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors, Diuretics) and Distribution Channel (Hospital Pharmacies, Drug Stores/OTC, E-Commerce, Fertility Clinics). The contraceptive drug class segment is expected to witness 1.6X increase in revenue by the end of 2024 and is projected to register a CAGR of 5.4% over the forecast period – reaching a market value of US$ 355.7 Mn by the end of 2024. The insulin sensitizing agent segment is estimated to register a CAGR of 4.8% during the forecast period. The Anti-Depressants drug class segment is estimated to be valued at US$ 51.1 Mn by the end of 2016, registering a CAGR of 3.0%.
Among distribution channels, the hospital pharmacies segment is estimated to account for 48.3% market share by 2016, which is anticipated to increase to 49.8% by 2024. This segment is expected to continue to lead the market in terms of revenue growth. The E-commerce segment is estimated to be valued at US$ 118.8 Mn by 2016 and is expected to expand at a CAGR of 4.3%.
The global PCOS drugs market has been segmented into five major regions namely North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. In terms of value, North America and Europe are estimated to dominate the market, collectively accounting for ~57% share of the overall market by the end of 2016. Latin America and Asia Pacific are estimated to be the fastest growing emerging markets. Revenue from the APAC market is expected to expand at a robust CAGR of 5.5% during the forecast period.
PCOS drugs market leaders
Some of the key players operating in the global PCOS drugs drug market include Sanofi, Novartis, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and AstraZeneca Plc. As there are no FDA approved drugs available in the market for the treatment of PCOS, leading companies are investing in R&D activities to develop a novel drug for treating PCOS. Moreover, companies are focusing on creating awareness related to feminine hygiene through CSR initiatives in developing regions such as APAC and MEA.